EP4247804A1 — Polyheterocyclic glp-1 r modulating compounds
Assigned to Gilead Sciences Inc · Expires 2023-09-27 · 3y expired
What this patent protects
The present disclosure provides glucagon-like peptide-1 receptor (GLP-1R) agonists of Formula (l-A), as well as pharmaceutical compositions and therapeutic uses thereof. The compounds are generally useful for treating a GLP-1R mediated disease or condition in a human such as non-…
USPTO Abstract
The present disclosure provides glucagon-like peptide-1 receptor (GLP-1R) agonists of Formula (l-A), as well as pharmaceutical compositions and therapeutic uses thereof. The compounds are generally useful for treating a GLP-1R mediated disease or condition in a human such as non-alcoholic steatohepatitis (NASH), obesity or type 2 diabetes.
Drugs covered by this patent
- Komzifti (ZIFTOMENIB) · Kura
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.